Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Foghorn Therapeutics
Biotech
Mirati CEO exits—Chutes & Ladders
Mirati CEO Meek steps down. Two more Illumina execs depart. Foghorn to switch up CMO.
Max Bayer
,
Gabrielle Masson
Aug 11, 2023 9:30am
Foghorn sinks eye tumor plans after glimpsing phase 1 data
Jun 28, 2023 8:45am
Foghorn has route back to clinic after FDA lifts yearlong hold
Jun 5, 2023 9:20am
FDA places partial hold on second Foghorn cancer drug trial
Apr 24, 2023 9:14am
Foghorn downgraded to full hold on AML/MDS med clouded by deaths
Aug 23, 2022 10:35am
Death triggers FDA hold on Foghorn blood cancer clinical trial
May 20, 2022 6:14am